Singular Genomics Systems, Inc. announced the formation of its scientific advisory board. The SAB comprises a distinguished group of academic and industry experts who will advise on the company's product and service offerings and research and development pipeline. The members of Singular's SAB include: David L. Barker, Ph.D., Board Member of Singular Genomics, AmideBio, and Aspen Neuroscience, Scientific Advisor to Luna DNA, and Board Member and Chairman at Bionano Genomics.

Dr. Barker previously served as Vice President and Chief Scientific Officer of Illumina, while also sitting on their Scientific Advisory Board. Lawrence Fong, M.D., Efim Guzik Distinguished Professor in Cancer Biology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF); Co-Director of the Parker Institute of Cancer Immunotherapy at UCSF; Co-Lead of the Cancer Immunity and Immunotherapy Program in the UCSF Cancer Center. Dr. Fong is also a physician-scientist in the Department of Medicine, Division of Hematology/Oncology at UCSF, where he directs both a translational research program and an NIH-funded research lab.

Dr. Fong's research examines the mechanisms that underlie clinical response and resistance to immunotherapies. David H. Ledbetter, Ph.D., FACMG, DABMGG, Chief Clinical & Research Officer at Unified Patient Network, Inc.Dr. Ledbetter also served as Executive Vice President and Founding Chief Scientific Officer at Geisinger, where he helped lead their MyCode biobank/genomics project – one of the largest in the world. Dr. Ledbetter's current research focuses on leveraging longitudinal electronic health information with large-scale DNA sequencing to determine the clinical utility and cost-effectiveness of precision medicine approaches in real-world health system settings.

Elaine Mardis, Ph.D., Board Member of Singular Genomics; Co-Executive Director of the Institute of Genomic Medicine at Nationwide Children's Hospital and holds the Steve and Cindy Rasmussen Endowed Chair in Genomic Medicine. Dr. Mardis is also Professor of Pediatrics at The Ohio State University College of Medicine. Additionally, Dr. Mardis serves on the Supervisory Board, Science and Technology Committee, and the Compensation and Human Resources Committee at Qiagen.

Daniel Shoemaker, Ph.D., former Chief Scientific Officer of Fate Therapeutics. Dr. Shoemaker has worked in the industry for over 25 years, helping to build several successful organizations ranging from startups to public companies. Most recently at Fate, he led the company's innovation efforts to bring multiple iPSC-derived cell therapies to the clinic.

Previously, Dr. Shoemaker served as Chief Scientific Officer of ICx Biosystems, a biotechnology firm that developed advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. He was also a founding scientist at Rosetta Inpharmatics. Dr. Shoemaker received his BS in biochemistry from the University of California, Santa Barbara and his Ph.D. in biochemistry from Stanford University.